Cerebrospinal fluid biomarkers as predictors of multiple sclerosis severity
Authors:
- 11 January 2025
- journal article
- research article
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 94, 106268
Abstract
No abstract availableKeywords
Funding Information
- Foundation for Barnes-Jewish Hospital
This publication has 53 references indexed in Scilit:
- Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trialsEBioMedicine, 2023
- Soluble TREM2: Innocent bystander or active player in neurological diseases?Neurobiology of Disease, 2022
- CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosisAnnals of Clinical and Translational Neurology, 2021
- Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteriaThe Lancet Neurology, 2018
- Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosisAnnals of Neurology, 2017
- Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation statusActa Neuropathologica, 2016
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- The prognostic significance of cerebrospinal fluid in multiple sclerosisJournal of the Neurological Sciences, 2009
- Blockade of TREM‐2 exacerbates experimental autoimmune encephalomyelitisEuropean Journal of Immunology, 2007
- Oligoclonal bands in multiple sclerosis cerebrospinal fluid: An update on methodology and clinical usefulnessJournal of Neuroimmunology, 2006